Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer
Cancers · 30.01.2026 · 18 (3) · 464
DOI: 10.3390/cancers18030464 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.01.2026. Verfasst von Shaimaa Alharbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 244 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sharjah, ASPIRE Precision Medicine Research Institute Abu Dhabi.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high immunogenicity and specific immune signatures. Although these molecular features including elevated tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1) expression provide a strong rationale for immunotherapy, clinical response remains limited due to multiple mechanisms of immune escape. This review summarizes current and emerging immunotherapeutic strategies in TNBC, including immune checkpoint inhibitors (PDL-1 and cytotoxic T-lymphocyte-associated protein 4 (CTL-4) blockade), adoptive cell therapy (ACT) (chimeric antigen receptor T-cell therapy (CAR-T) and TIL therapy), oncolytic virotherapy, and antibody-based approaches. We also discuss the mechanisms of resistance including DNA damage response alterations, anti-apoptotic signaling, and tumor microenvironment-mediated resistance. Finally, we highlight rational combination strategies, immunotherapy with chemotherapy, targeted therapy, or additional immunotherapies that aim to enhance response to immunotherapy. Ongoing advances in immunotherapy hold significant potential to improve outcomes for patients with TNBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- BIMAI (Biomedically-InforMed Artificial Intelligence) Laboratory, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- Center of Excellence for Precision Medicine, Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.
- Division of Surgery and Interventional Science, University College London, London NW3 2PF, UK.
ORCID-Profile: Nourhan E Omran, Rifat Hamoudi, Rania Harati
Förderung
- University of Sharjah
- ASPIRE Precision Medicine Research Institute Abu Dhabi
Zitieren
APA
Alharbi, S., Qasem, F. F., Talebi, M. T., Omran, N. E., Hamoudi, R., & Harati, R. (2026). Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer. Cancers, 18(3), 464. https://doi.org/10.3390/cancers18030464
Vancouver
Alharbi S, Qasem FF, Talebi MT, Omran NE, Hamoudi R, Harati R. Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer. Cancers. 2026;18(3):464. doi:10.3390/cancers18030464
BibTeX
@article{Alharbi2026,
author = {Alharbi, Shaimaa and Qasem, Farah Faozi and Talebi, Mahsa Taleb and Omran, Nourhan E and Hamoudi, Rifat and Harati, Rania},
title = {Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {3},
pages = {464},
doi = {10.3390/cancers18030464}
}
EUVIMED